Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
362.5 DKK | -1.81% | +0.55% | -6.55% |
Apr. 12 | Chemometec A/S Reports Revenue for the Third Quarter and First Nine Months of 2023 -2024 | CI |
Apr. 12 | ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an expected P/E ratio at 50.4 and 42.05 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.55% | 932M | D | ||
+75.33% | 12.54B | B- | ||
-24.19% | 7.39B | C+ | ||
+6.43% | 6.62B | C- | ||
+13.59% | 5.43B | D+ | ||
+34.82% | 4.81B | - | ||
-14.78% | 4.8B | B | ||
-25.57% | 3.72B | B- | ||
-26.93% | 2.76B | C | ||
+49.43% | 2.4B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHEMM Stock
- Ratings ChemoMetec A/S